Summary:
- Genmab and AbbVie have announced positive top-line results from a Phase 3 clinical trial (EPCORE DLBCL-2) evaluating the efficacy of epcoritamab in combination with R-CHOP for the treatment of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
- The study met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival (PFS) for patients receiving the combination therapy compared to the standard-of-care R-CHOP regimen alone.
- These findings represent a significant advancement in hematology-oncology, suggesting that bispecific antibody integration into frontline chemoimmunotherapy may improve outcomes for patients with aggressive B-cell malignancies.